Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910152 · ClinicalTrials.gov registry record · Phase 1
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
A Phase 1 study, sponsored by Hannah Choe, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT04910152: Clinical Trial Phase 1 study, sponsored by Hannah Choe, MD.
NCT04910152 is a Phase 1 study that was terminated before completion, run by Hannah Choe, MD. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04910152, a Phase 1 study, was terminated before completion, sponsored by Hannah Choe, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD). PLX51107 is a novel, potent non-benzodiazepine structured small molecule BET inhibitor with a unique binding mode selective for BRD4 inhibition and a more tolerable side effect profile. PLX51107 may work better in treating steroid-refractory acute GVHD.
Interventions
- DRUG BRD4 Inhibitor PLX51107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 1 |
Why NCT04910152 stopped before completion
NCT04910152 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which BRD4 Inhibitor PLX51107 is the first listed.
NCT04910152 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04910152 about?
NCT04910152 is a clinical study titled "Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD". This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD). PLX51107 is a novel, potent non-benzodiazepine structured small molecule BET inhibitor with a unique binding mode selective for BRD4 inhibition and a more tolerable side...
What is the current status of trial NCT04910152?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2022-04-19. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT04910152?
The interventions under investigation include: BRD4 Inhibitor PLX51107 (DRUG).
Who is sponsoring clinical trial NCT04910152?
This trial is sponsored by Hannah Choe, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04910152's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI